These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Intravenous Antibiotic and Antifungal Agent Pharmacokinetic-Pharmacodynamic Dosing in Adults with Severe Burn Injury. Cota JM; FakhriRavari A; Rowan MP; Chung KK; Murray CK; Akers KS Clin Ther; 2016 Sep; 38(9):2016-31. PubMed ID: 27586127 [TBL] [Abstract][Full Text] [Related]
3. The contribution of pharmacokinetic-pharmacodynamic modelling with Monte Carlo simulation to the development of susceptibility breakpoints for Neisseria meningitidis. Burgess DS; Frei CR; Lewis Ii JS; Fiebelkorn KR; Jorgensen JH Clin Microbiol Infect; 2007 Jan; 13(1):33-9. PubMed ID: 17184285 [TBL] [Abstract][Full Text] [Related]
4. Comparison of antimicrobial pharmacokinetic/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria. Asín E; Isla A; Canut A; Rodríguez Gascón A Int J Antimicrob Agents; 2012 Oct; 40(4):313-22. PubMed ID: 22921422 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics-pharmacodynamics, computer decision support technologies, and antimicrobial stewardship: the compass and rudder. Owens RC; Bulik CC; Andes DR Diagn Microbiol Infect Dis; 2018 Aug; 91(4):371-382. PubMed ID: 29776710 [TBL] [Abstract][Full Text] [Related]
6. Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. Frei CR; Wiederhold NP; Burgess DS J Antimicrob Chemother; 2008 Mar; 61(3):621-8. PubMed ID: 18252694 [TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time. Dudley MN; Ambrose PG Curr Opin Microbiol; 2000 Oct; 3(5):515-21. PubMed ID: 11050452 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic (PK-PD) modeling and the rational selection of dosage regimes for the prudent use of antimicrobial drugs. Papich MG Vet Microbiol; 2014 Jul; 171(3-4):480-6. PubMed ID: 24513278 [TBL] [Abstract][Full Text] [Related]
10. Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents. Asín-Prieto E; Rodríguez-Gascón A; Isla A J Infect Chemother; 2015 May; 21(5):319-29. PubMed ID: 25737147 [TBL] [Abstract][Full Text] [Related]
11. Correlation of pharmacokinetic/pharmacodynamic-derived predictions of antibiotic efficacy with clinical outcomes in severely ill patients with Pseudomonas aeruginosa pneumonia. Fish DN; Kiser TH Pharmacotherapy; 2013 Oct; 33(10):1022-34. PubMed ID: 23744833 [TBL] [Abstract][Full Text] [Related]
12. [PK/PD analysis and proper dosage of antimicrobial agents for effective and safe treatment of infectious diseases]. Hori S Yakugaku Zasshi; 2007 Jun; 127(6):931-7. PubMed ID: 17541242 [TBL] [Abstract][Full Text] [Related]
13. [The proper use of quinolones to the elderly patient with community-acquired pneumonia examined by Monte Carlo simulation]. Yanagihara K; Morinaga Y; Fukushima K; Nakamura S; Kurihara S; Seki M; Izumikawa K; Kakeya H; Yamamoto Y; Miyazaki Y; Hirakata Y; Tashiro T; Kohno S Jpn J Antibiot; 2007 Oct; 60(5):251-6. PubMed ID: 18198653 [TBL] [Abstract][Full Text] [Related]
15. Clinical Pharmacokinetics of Levornidazole in Elderly Subjects and Dosing Regimen Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis. Guo B; He G; Wu X; Yu J; Cao G; Li Y; Fan Y; Chen Y; Shi Y; Zhang Y; Zhang J Clin Ther; 2017 Jul; 39(7):1336-1346. PubMed ID: 28619503 [TBL] [Abstract][Full Text] [Related]
16. The importance of appropriate antimicrobial dosing: pharmacokinetic and pharmacodynamic considerations. Preston SL Ann Pharmacother; 2004 Sep; 38(9 Suppl):S14-8. PubMed ID: 15226489 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer. Theuretzbacher U Clin Infect Dis; 2012 Jun; 54(12):1785-92. PubMed ID: 22437238 [TBL] [Abstract][Full Text] [Related]
18. [Dosing regimen rationalization of biapenem in pediatric patients: use of Monte Carlo simulation]. Kameda K; Miki M; Ikawa K; Morikawa N; Kobayashi M Jpn J Antibiot; 2009 Feb; 62(1):1-8. PubMed ID: 19378765 [TBL] [Abstract][Full Text] [Related]
19. The integration of pharmacokinetics and pathogen susceptibility data in the design of rational dosing regimens. Maglio D; Nicolau DP Methods Find Exp Clin Pharmacol; 2004 Dec; 26(10):781-8. PubMed ID: 15672121 [TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]